MedPath

Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring

Not Applicable
Completed
Conditions
Type 2 Diabetes
Registration Number
NCT01072565
Lead Sponsor
HealthPartners Institute
Brief Summary

The purpose of this study is to evaluate the effectiveness of Self Monitoring of Blood Glucose (SMBG) for clinical decisions related to the management of type 2 diabetes and to determine the benefit of using Continuous Glucose Monitoring (CGM) for clinical diabetes management.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
91
Inclusion Criteria
  • Male or female subjects ≥18 and ≤75 years of age
  • Clinical diagnosis of diabetes
  • Diabetes duration ≥ 1 year
  • HbA1c ≥7.2%
  • Diabetes can be treated with any therapy including medical nutrition therapy alone and any pharmaceutical therapy
Exclusion Criteria
  • Taken prednisone or cortisone medications in the previous 30 days
  • Currently pregnant or planning pregnancy during the study period
  • Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study
  • Unable to follow the study protocol
  • Unable to speak, read and write in English

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Primary Outcome Measures
NameTimeMethod
Evaluate the efficacy of SMBG for clinical decisions related to the management of type 2 diabetes.Three, six and nine months.
Secondary Outcome Measures
NameTimeMethod
Determine the incremental benefit of CGM for clinical decision-making.Three, six and nine months.

Trial Locations

Locations (1)

International Diabetes Center

🇺🇸

Minneapolis, Minnesota, United States

International Diabetes Center
🇺🇸Minneapolis, Minnesota, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.